AU2017267732B2 - Treatment of Meniere's disease - Google Patents

Treatment of Meniere's disease Download PDF

Info

Publication number
AU2017267732B2
AU2017267732B2 AU2017267732A AU2017267732A AU2017267732B2 AU 2017267732 B2 AU2017267732 B2 AU 2017267732B2 AU 2017267732 A AU2017267732 A AU 2017267732A AU 2017267732 A AU2017267732 A AU 2017267732A AU 2017267732 B2 AU2017267732 B2 AU 2017267732B2
Authority
AU
Australia
Prior art keywords
ebselen
subject
composition
compounds
tinnitus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017267732A
Other languages
English (en)
Other versions
AU2017267732A1 (en
Inventor
Jonathan Kil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sound Pharmaceuticals Inc
Original Assignee
Sound Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sound Pharmaceuticals Inc filed Critical Sound Pharmaceuticals Inc
Publication of AU2017267732A1 publication Critical patent/AU2017267732A1/en
Application granted granted Critical
Publication of AU2017267732B2 publication Critical patent/AU2017267732B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2017267732A 2016-05-18 2017-05-18 Treatment of Meniere's disease Active AU2017267732B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662338443P 2016-05-18 2016-05-18
US62/338,443 2016-05-18
PCT/US2017/033379 WO2017201318A1 (en) 2016-05-18 2017-05-18 Treatment of meniere's disease

Publications (2)

Publication Number Publication Date
AU2017267732A1 AU2017267732A1 (en) 2018-12-20
AU2017267732B2 true AU2017267732B2 (en) 2023-04-13

Family

ID=60326098

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017267732A Active AU2017267732B2 (en) 2016-05-18 2017-05-18 Treatment of Meniere's disease

Country Status (19)

Country Link
US (1) US12427138B2 (enExample)
EP (2) EP4461360A3 (enExample)
JP (1) JP7100866B2 (enExample)
KR (1) KR102474830B1 (enExample)
CN (1) CN109475518A (enExample)
AU (1) AU2017267732B2 (enExample)
CA (1) CA3026007A1 (enExample)
DK (1) DK3458045T3 (enExample)
ES (1) ES2990157T3 (enExample)
FI (1) FI3458045T3 (enExample)
HR (1) HRP20241559T1 (enExample)
HU (1) HUE069280T2 (enExample)
LT (1) LT3458045T (enExample)
PL (1) PL3458045T3 (enExample)
PT (1) PT3458045T (enExample)
RS (1) RS66167B1 (enExample)
SI (1) SI3458045T1 (enExample)
SM (1) SMT202400469T1 (enExample)
WO (1) WO2017201318A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115135321B (zh) 2020-02-24 2023-12-05 上海科技大学 N-取代吡啶基苯并异硒唑酮化合物的应用
WO2023122719A2 (en) * 2021-12-23 2023-06-29 University Of Rochester Csf transport pathway for delivery of agents to inner ear
WO2023240094A1 (en) 2022-06-06 2023-12-14 Sound Pharmaceuticals Inc. Amorphous dosage form containing ebselen
EP4536191A1 (en) * 2022-06-06 2025-04-16 Sound Pharmaceuticals Incorporated Ebselen containing oral dosage forms

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220145A1 (en) * 2002-01-04 2004-11-04 Sound Pharmaceuticals Incorporated Methods for treating hearing loss
WO2007044700A2 (en) * 2005-10-07 2007-04-19 Board Of Trustees Of Southern Illinois University Protectant combinations for reducing toxicities
WO2018005830A1 (en) * 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3827093A1 (de) 1988-08-10 1990-02-15 Nattermann A & Cie Verfahren zur herstellung von hochreinem ebselen
JPH02202818A (ja) 1988-12-09 1990-08-10 Allergan Inc 白内障の治療における２―置換―チアゾリジン―４―カルボン酸類の用途
JP5236641B2 (ja) 2006-07-25 2013-07-17 ハフ イヤ インスティテュート 急性音響外傷の治療方法
US20110142834A1 (en) 2008-05-15 2011-06-16 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments using compounds having erythropoietin activity
AU2009330458B2 (en) 2008-12-22 2013-08-22 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
ES2893825T3 (es) 2011-02-04 2022-02-10 Hough Ear Inst Métodos de tratamiento de lesiones cerebrales
CA2842106A1 (en) 2011-07-28 2013-01-31 Promentis Pharmaceuticals, Inc. Cysteine prodrugs
CN102526734A (zh) 2012-01-12 2012-07-04 王玉丰 治疗年龄相关性听力损失的药物组合物及其应用
WO2015200768A2 (en) * 2014-06-26 2015-12-30 Auris Medical Ag Pharmacologic treatments of menière's disease
CA2961380A1 (en) * 2014-09-15 2016-03-24 Sound Pharmaceuticals Incorporated Methods and compositions for treating psychotic disorders
US10750005B2 (en) 2018-09-27 2020-08-18 International Business Machines Corporation Selective email narration system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220145A1 (en) * 2002-01-04 2004-11-04 Sound Pharmaceuticals Incorporated Methods for treating hearing loss
WO2007044700A2 (en) * 2005-10-07 2007-04-19 Board Of Trustees Of Southern Illinois University Protectant combinations for reducing toxicities
WO2018005830A1 (en) * 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEBASHREE MUKHERJEA ET AL: "Early investigational drugs for hearing loss", EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 24, no. 2, 22 September 2014 (2014-09-22), UK, pages 201 - 217 *
ELIE DOLGIN: "Sound Medicine", 1 May 2012 (2012-05-01), XP055642318, Retrieved from the Internet [retrieved on 20191113], DOI: 10.1038/nm0512-642 *

Also Published As

Publication number Publication date
KR20190043499A (ko) 2019-04-26
EP3458045A1 (en) 2019-03-27
JP7100866B2 (ja) 2022-07-14
AU2017267732A1 (en) 2018-12-20
EP4461360A2 (en) 2024-11-13
SMT202400469T1 (it) 2025-01-14
CA3026007A1 (en) 2017-11-23
RS66167B1 (sr) 2024-12-31
EP3458045A4 (en) 2020-09-16
LT3458045T (lt) 2024-12-10
US20200261417A1 (en) 2020-08-20
DK3458045T3 (da) 2024-11-04
US12427138B2 (en) 2025-09-30
SI3458045T1 (sl) 2025-03-31
CN109475518A (zh) 2019-03-15
FI3458045T3 (fi) 2024-10-24
ES2990157T3 (es) 2024-11-29
KR102474830B1 (ko) 2022-12-06
PL3458045T3 (pl) 2025-01-07
HRP20241559T1 (hr) 2025-02-14
PT3458045T (pt) 2024-10-28
EP3458045B1 (en) 2024-08-21
EP4461360A3 (en) 2025-01-22
WO2017201318A1 (en) 2017-11-23
HUE069280T2 (hu) 2025-02-28
JP2019516727A (ja) 2019-06-20

Similar Documents

Publication Publication Date Title
US10835546B2 (en) App specific BACE inhibitors (ASBIs) and uses thereof
CN103974619B (zh) 治疗法布里病的给药方案
AU2017267732B2 (en) Treatment of Meniere's disease
CN102802418A (zh) 用于治疗肌萎缩性侧索硬化的组合物和方法
JP2023169413A (ja) 精神病性障害を治療するための方法および組成物
US20160022632A1 (en) Combination of canagliflozin and probenecid for the treament of hyperuricemia
KR20240099179A (ko) 만성 비부비동염을 치료하기 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복스아미드
AU2015223908B2 (en) Progress-Suppressing or Improving Agent for Chronic Kidney Disease
JP2017078089A (ja) 過活動膀胱の治療のためのソリフェナシンと唾液分泌刺激剤の組合せ
US20240245666A1 (en) Dosing regimens
WO1998008504A1 (en) Remedies for allergic dermatitis
JP2014513689A (ja) 過活動膀胱の治療のためのトロスピウムと唾液分泌刺激剤の組合せ
US20250041315A1 (en) Levonorgestrel butanoate formulation and methods relating thereto
WO2025110992A1 (en) Method of administering belumosudil for patient subpopulations with hepatic impairment
WO2025018279A1 (ja) ヒト移植片対宿主病の治療薬およびその組合せ物
WO2004105760A1 (en) Use of efletirizine for treating persistent allergic rhinitis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 18 MAY 2024 TO 18 MAR 2025 IN WHICH TO PAY A RENEWAL FEE HAS BEEN FILED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A RENEWAL FEE HAS BEEN EXTENDED TO 18 MAR 2025